Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity

Immu-SI Press Release

– Phase 3 Program of IMU-838 in Relapsing-Remitting Multiple Sclerosis Expected to Begin in the Second Half of 2021– – Reported Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis – – Announced Main Analysis of Phase 2 CALVID-1 Trial of IMU-838 Showing Evidence of Clinical Activity in Patients with Moderate COVID-19 – …

Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

Immu-SI Press Release

– Statistically Significant Decrease in Serum Alkaline Phosphatase (ALP) Levels in the Per-Protocol Population After 24-Week IMU-838 Treatment, as Compared to Baseline – – Primary Objective of Therapeutic Benefit Achieved in 27.3% of the Patients of the Per-Protocol Population at Week 24 – – Other Liver Biochemistry Parameters Remained Stable – – IMU-838’s Favorable Safety and Tolerability Profile Confirmed in …

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

Immu-SI Press Release

– Clinical Activity of IMU-838 Confirmed Based on Multiple Secondary Endpoints, Including Clinically Meaningful Improvements in Time to Clinical Recovery and Clinical Improvement – – Primary and Key Secondary Endpoints Were Not Evaluable Due to the Very Low Rates of Serious Complications in the Population of Hospitalized Patients With Moderate COVID-19 – – High-Risk Patients and Patients Aged Over 65 …

Immunic, Inc. to Participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25

Immu-SI Press Release

NEW YORK, February 11, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference, on Thursday, February 25, …

Development of Innovative COVID-19 Therapies Needs Additional Public Funding to Help Patients in the Short-Term (in German Only)

Immu-SI Press Release

Entwicklung innovativer COVID-19-Medikamente bedarf weitergehender öffentlicher Förderung, um Patienten schnell zu helfen Steigende Todeszahlen zeigen den hohen Bedarf an wirksamen Medikamenten, um COVID-19-Patienten zu versorgen und Krankenhäuser zu entlasten BEAT-COV begrüßt Bereitstellung von Fördermitteln für Medikamentenentwicklung durch das BMBF als ersten wichtigen Schritt, jedoch sind noch weitere entscheidende Bausteine in der öffentlichen Förderung und zur Erreichung des Förderziels erforderlich Um …

Immunic, Inc. to Participate in Investor Conferences in January

Immu-SI Press Release

– Management Provides Update on Timing of Data for IMU-838 in Primary Sclerosing Cholangitis – NEW YORK, January 5, 2021 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced management’s participation in the following investor conferences in January: January 11-14: H.C. Wainwright BioConnect 2021 …

Immunic, Inc. Added to NASDAQ Biotechnology Index

Immu-SI Press Release

NEW YORK, December 14, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020. The NASDAQ Biotechnology Index is designed …

BEAT-COV Initiative Requests Support for the Development and Production of New, Innovative COVID-19 Therapies (in German Only)

Immu-SI Press Release

Aufzeichnung der Pressekonferenz: vimeo.com/486379519 Initiative BEAT-COV fordert Unterstützung für Entwicklung und Produktion neuer, innovativer COVID-19-Medikamente Sichere und hoch wirksame Medikamente sind dringend erforderlich, um COVID-19-Patienten zu versorgen und Krankenhäuser zu entlasten. Impfstoffe schützen vor Erkrankung, aber bereits Erkrankte benötigen dringend Medikamente für eine gezielte Therapie von Symptomen und eine Verbesserung der Überlebenschancen. Es fehlt die zielgerichtete Förderung von in der …

Immunic, Inc. to Participate in Investor Conferences in December

Immu-SI Press Release

NEW YORK, November 24, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced management’s participation in the following investor conferences in December: November 30 – December 3: Piper Sandler 32nd Virtual Healthcare Conference. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, …

Immunic, Inc. Announces Formation of Scientific-Medical Advisory Board

Immu-SI Press Release

– Initial Appointments Include Internationally Recognized Experts: Fred D. Lublin, M.D.; Bruce E. Sands, M.D., M.S.; Jerrold R. Turner, M.D., Ph.D. and Paul J. Utz, M.D. – NEW YORK, November 17, 2020 – Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the formation of …